← Back to screener

TG THERAPEUTICS, INC. TGTX

Rank #2030 · Nasdaq · $9.4B market cap
Audited by KPMG LLP, no going-concern flag in the latest filing.
Score
35.8
P/E
739.1
P/B
159.86
ROE
21.6%
Op. Margin
8.8%
Debt Ratio
606%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E 739.1x, P/B 159.86x. Ranks in the top 79% of the universe.

Profitability ★★★☆☆
Good

ROE 21.6%. Ranks in the top 33% of the universe.

Safety ★☆☆☆☆
Poor

Debt ratio 606%. Ranks in the top 82% of the universe. Above 200% signals meaningful leverage risk.

Growth ★★★★★
Excellent

Revenue growth of 8290.0% year over year. Ranks in the top 0% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011–$-0.0B$-0.0B$0.0B–65
2012–$-0.0B$-0.0B$0.0B–51
2013–$-0.0B$-0.0B$0.0B–68
2014–$-0.0B$-0.0B$0.0B–52
2015–$-0.0B$-0.0B$0.0B–43
2016–$-0.1B$-0.1B$0.0B–30
2017–$-0.1B$-0.1B$0.1B–24
2018$0.0B$-0.1B$-0.1B$0.1B-51953.330
2019$0.0B$-0.1B$-0.1B$0.0B-78100.0166
2020$0.0B$-0.2B$-0.2B$0.1B-114736.8186
2021$0.0B$-0.2B$-0.2B$0.0B-111220.4442
2022$0.0B$-0.3B$-0.3B$0.0B-179996.1369
2023$0.0B$-0.3B$-0.3B$0.5B-5154.326
2024$0.0B$-0.2B$-0.2B$0.2B-7839.071
2025$0.2B$0.0B$0.0B$0.1B8.8606

← See the full screener